Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Three University of Oxford spinouts have raised significant investment to scale their companies in vehicle automation, quantum computing and medical imaging respectively.

Oxford Ionics founders
  • Oxbotica, a leader in autonomous vehicle software for businesses, has raised US$140 million 
  • Oxford Ionics, whose innovations are taking quantum computing a step closer to reality, has raised £30 million
  • Perspectum, an AI driven medical imaging company, has raised US$36 million

Perspectum, founded in 2012, is a precision health company which develops medical imaging tools to improve the diagnoses of metabolic diseases and cancer. It was born out of a discovery made by Dr Rajarshi Banerjee, now CEO of Perspectum, when researching how to improve the use of MRI in cardiology for his DPhil at the University of Oxford. Read more about the discovery here.

The new $36 million investment was led by Oppenheimer Holdings and completes the first close of its Series C funding round. This brings the total amount raised since inception to around $120 million.

"This new funding will help us to continue innovating new products that will make healthcare safer by providing non-invasive alternatives to biopsy, totally changing how and when we can see and treat many diseases," says Dr Rajarshi Banerjee, founder and CEO of Perspectum. 

Read about the other two spin-outs and the full story on the University of Oxford website. 

Similar stories

The Nuffield Department of Women's & Reproductive Health's Clinical Research Group recruits its 2,000th participant to the Generation Study

Oxford’s Clinical Research Group (CRG) has reached an important milestone after recruiting its 2,000th participant to the nationwide Generation Study.

Dementias Platform UK (DPUK) blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.

Robotic hip and knee surgery fails to cut overall risk of repeat surgery

Two major studies from the University of Oxford, Queen Mary University of London and the University of Bristol, have found that robotic-assisted hip and knee replacement does not reduce the overall early risk of repeat surgery compared with conventional surgery.

Oxford medical student takes AI safety message to the Palace of Versailles

Oxford medical student Julian Shellard has presented at an international workshop on the future of Artificial Intelligence (AI) at the Palace of Versailles in Paris, highlighting the important role medical students can play in global conversations on shaping the future of science and medicine.

Everyday DNA damage reveals a hidden weakness in some cancers

Researchers in the Chapman Group at the MRC Weatherall Institute of Molecular Medicine, have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.

Dunn School publishes new children’s book to mark centenary

The collaboration with Oxford University Press brings the story of the development of Penicillin to a new audience